<p>Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股票在周二交易前出现了跳空上涨。该股票之前收盘价为 21.30 美元，但开盘价为 22.19 美元。Arcus Biosciences 的股票最后交易价格为 22.4330 美元，成交量为 1,292,918 股。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>从滞后者到领头羊：小型股正在崛起</li>
</ul>
<p>RCUS 最近成为多份研究报告的主题。Truist Financial 在 12 月 12 日的研究报告中将 Arcus Biosciences 的股票目标价设定为 30.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Arcus Biosciences 的 “卖出（d-）” 评级。Wells Fargo &amp; Company 在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。摩根士丹利在 1 月 8 日的报告中重申了 “持平” 评级，并将 Arcus Biosciences 的目标价设定为 20.00 美元（从 23.00 美元下调）。最后，高盛集团在周一将 Arcus Biosciences 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 16.00 美元上调至 28.00 美元。八位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标价为 30.00 美元。</p>
<p><strong>获取我们对 RCUS 的最新股票分析</strong></p>
<h2>Arcus Biosciences 股票上涨 4.8%</h2>
<ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
<p>该公司的市值为 24.1 亿美元，市盈率为-6.49，贝塔值为 0.77。公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该业务的 50 日移动平均价格为 22.62 美元，200 日移动平均价格为 15.72 美元。</p>
<p>Arcus Biosciences (NYSE:RCUS - 获取免费报告) 最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 (-1.27) 美元，超出分析师共识预期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。在去年同期，该公司每股收益为 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析师预计 Arcus Biosciences, Inc.在本年度将发布每股收益为-3.15 美元。</p>
<h2>内部买卖</h2>
<ul>
<li>吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹</li>
</ul>
<p>在相关消息中，首席执行官 Terry J. Rosen 于 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 633,360.36 美元。交易完成后，首席执行官直接持有公司 2,220,553 股，价值 48,585,699.64 美元。此次交易使其持股比例减少了 1.29%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席运营官 Jennifer Jarrett 于 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 245,603.00 美元。交易完成后，首席运营官直接持有公司 203,007 股，价值约 4,441,793.16 美元。此次交易使其持股比例减少了 5.24%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了 422,060 股公司股票，价值 9,286,202 美元。内部人士持有公司股票的比例为 9.60%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近买卖了该股票的股份。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前拥有 2,748 股公司股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前拥有 2,866 股公司股票，价值 39,000 美元，此前在上个季度又收购了 2,845 股。Abich Financial Wealth Management LLC 在第三季度购买了 Arcus Biosciences 的新股份，价值 69,000 美元。CWM LLC 在第二季度将其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前拥有 5,441 股公司股票，价值 44,000 美元，此前在上个季度又收购了 3,810 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前拥有 7,038 股公司股票，价值 57,000 美元，此前在上个季度又收购了 1,796 股。92.89% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Arcus Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Arcus Biosciences 是一家临床阶段的生物制药公司，专注于新型癌症免疫疗法的发现、开发和商业化。该公司的研究平台集中在通过小分子和抗体候选药物调节肿瘤微环境和免疫检查点。Arcus 旨在通过靶向腺苷轴和免疫细胞上的抑制受体等途径增强抗肿瘤免疫反应。</p>
<p>该公司的主要临床项目包括 etrumadenant，一种口服给药的 A2A 腺苷受体拮抗剂，正在与抗 PD-1 疗法联合评估，以及 domvanalimab，一种抗 TIGIT 单克隆抗体。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Arcus Biosciences</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活</li>
<li>股票代码揭晓：获得 “下一个埃隆·马斯克” 公司的首次公开募股机会</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 $1,000 在 Arcus Biosciences 吗？</h2>
<p>在您考虑 Arcus Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Arcus Biosciences 并不在名单上。</p>
<p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>Arcus Biosciences（纽约证券交易所代码：RCUS）股价在开盘前从 21.30 美元跳涨至 22.19 美元，最终收于 22.43 美元，成交量为 1,292,918 股。分析师们设定了不同的目标价，Truist Financial 为 30.00 美元，Wells Fargo 为 29.00 美元。该公司报告的季度收入为 2600 万美元，超出预期，但每股收益为负（1.27 美元）。公司高管进行了股票出售，首席执行官 Terry J. Rosen 出售了价值 633,360 美元的股票。机构投资者最近也增加了对该公司的持股</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $21.30, but opened at $22.19. Arcus Biosciences shares last traded at $22.4330, with a volume of 1,292,918 shares traded.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股票在周二交易前出现了跳空上涨。该股票之前收盘价为 21.30 美元，但开盘价为 22.19 美元。Arcus Biosciences 的股票最后交易价格为 22.4330 美元，成交量为 1,292,918 股。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从滞后者到领头羊：小型股正在崛起</li>
</ul>
</div><p>RCUS has been the subject of a number of recent research reports. Truist Financial set a $30.00 price objective on shares of Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Wells Fargo &amp; Company raised their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, October 20th. Morgan Stanley reiterated an &#34;equal weight&#34; rating and issued a $20.00 target price (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Finally, The Goldman Sachs Group upgraded shares of Arcus Biosciences from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price target for the company from $16.00 to $28.00 in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Arcus Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $30.00.</p>
<div class="lb-trans"><p>RCUS 最近成为多份研究报告的主题。Truist Financial 在 12 月 12 日的研究报告中将 Arcus Biosciences 的股票目标价设定为 30.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Arcus Biosciences 的 “卖出（d-）” 评级。Wells Fargo &amp; Company 在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。摩根士丹利在 1 月 8 日的报告中重申了 “持平” 评级，并将 Arcus Biosciences 的目标价设定为 20.00 美元（从 23.00 美元下调）。最后，高盛集团在周一将 Arcus Biosciences 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 16.00 美元上调至 28.00 美元。八位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标价为 30.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RCUS</strong></p>
<div class="lb-trans"><p><strong>获取我们对 RCUS 的最新股票分析</strong></p>
</div><h2>Arcus Biosciences Stock Up 4.8%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股票上涨 4.8%</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
</div><p>The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.49 and a beta of 0.77. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The business has a fifty day moving average price of $22.62 and a two-hundred day moving average price of $15.72.</p>
<div class="lb-trans"><p>该公司的市值为 24.1 亿美元，市盈率为-6.49，贝塔值为 0.77。公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该业务的 50 日移动平均价格为 22.62 美元，200 日移动平均价格为 15.72 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the prior year, the firm earned ($1.00) earnings per share. Arcus Biosciences's revenue for the quarter was down 45.8% on a year-over-year basis. On average, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Arcus Biosciences (NYSE:RCUS - 获取免费报告) 最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 (-1.27) 美元，超出分析师共识预期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。在去年同期，该公司每股收益为 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析师预计 Arcus Biosciences, Inc.在本年度将发布每股收益为-3.15 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹</li>
</ul>
</div><p>In related news, CEO Terry J. Rosen sold 28,947 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the transaction, the chief executive officer directly owned 2,220,553 shares in the company, valued at $48,585,699.64. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 11,225 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $245,603.00. Following the completion of the sale, the chief operating officer directly owned 203,007 shares in the company, valued at approximately $4,441,793.16. The trade was a 5.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $9,286,202 over the last 90 days. Insiders own 9.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Terry J. Rosen 于 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 633,360.36 美元。交易完成后，首席执行官直接持有公司 2,220,553 股，价值 48,585,699.64 美元。此次交易使其持股比例减少了 1.29%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席运营官 Jennifer Jarrett 于 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 245,603.00 美元。交易完成后，首席运营官直接持有公司 203,007 股，价值约 4,441,793.16 美元。此次交易使其持股比例减少了 5.24%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了 422,060 股公司股票，价值 9,286,202 美元。内部人士持有公司股票的比例为 9.60%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after buying an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company's stock worth $39,000 after acquiring an additional 2,845 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in Arcus Biosciences in the third quarter valued at $69,000. CWM LLC lifted its position in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company's stock valued at $44,000 after acquiring an additional 3,810 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock valued at $57,000 after acquiring an additional 1,796 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近买卖了该股票的股份。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前拥有 2,748 股公司股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前拥有 2,866 股公司股票，价值 39,000 美元，此前在上个季度又收购了 2,845 股。Abich Financial Wealth Management LLC 在第三季度购买了 Arcus Biosciences 的新股份，价值 69,000 美元。CWM LLC 在第二季度将其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前拥有 5,441 股公司股票，价值 44,000 美元，此前在上个季度又收购了 3,810 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前拥有 7,038 股公司股票，价值 57,000 美元，此前在上个季度又收购了 1,796 股。92.89% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.</p>
<div class="lb-trans"><p>Arcus Biosciences 是一家临床阶段的生物制药公司，专注于新型癌症免疫疗法的发现、开发和商业化。该公司的研究平台集中在通过小分子和抗体候选药物调节肿瘤微环境和免疫检查点。Arcus 旨在通过靶向腺苷轴和免疫细胞上的抑制受体等途径增强抗肿瘤免疫反应。</p>
</div><p>The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.</p>
<div class="lb-trans"><p>该公司的主要临床项目包括 etrumadenant，一种口服给药的 A2A 腺苷受体拮抗剂，正在与抗 PD-1 疗法联合评估，以及 domvanalimab，一种抗 TIGIT 单克隆抗体。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Arcus Biosciences</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活</li>
<li>股票代码揭晓：获得 “下一个埃隆·马斯克” 公司的首次公开募股机会</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 $1,000 在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Arcus Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcus Biosciences (NYSE:RCUS) 股价跳空上涨 - 事情的经过